李岐佩,高 庆,王益东,王娟妮,阎 仿.孕三烯酮联合米非司酮对子宫内膜异位症患者血清VEGF、MMP-9、sICAM-1水平的影响[J].现代生物医学进展英文版,2019,19(18):3559-3562. |
孕三烯酮联合米非司酮对子宫内膜异位症患者血清VEGF、MMP-9、sICAM-1水平的影响 |
Clinical Efficacy of Trienone Combined with Mifepristone in the Treatment of Endometriosis and its Effects on the Serum Levels of VEGF, MMP-9, sICAM-1 |
Received:May 30, 2019 Revised:June 23, 2019 |
DOI:10.13241/j.cnki.pmb.2019.18.035 |
中文关键词: 子宫内膜异位症 米非司酮 孕三烯酮 血管内皮生长因子 基质金属蛋白酶-9 可溶性细胞黏附因子-1 |
英文关键词: Endometriosis Mifepristone Trienone Vascular endothelial growth factor Matrix metalloprotein-9 Soluble Intercellular adhesion molecule-1 |
基金项目:陕西省重点研发计划项目(2019SF-021) |
Author Name | Affiliation | E-mail | LI Qi-pei | Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China | wangyf197204@163.com | GAO Qing | Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China | | WANG Yi-dong | Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China | | WANG Juan-ni | Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China | | YAN Fang | Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China | |
|
Hits: 694 |
Download times: 541 |
中文摘要: |
摘要 目的:研究孕三烯酮联合米非司酮治疗子宫内膜异位症患者的临床效果及对患者血清血管内皮生长因子(vascular endothelial growth factor,VEGF)、基质金属蛋白酶-9(matrix metalloprotein-9,MMP-9)、可溶性细胞黏附因子-1((soluble Intercellular adhesion molecule-1,sICAM-1)水平的影响。方法:选择2017年6月至2018年10月在我院进行治疗的子宫内膜异位症患者96例,根据治疗方案不同分为观察组和对照组,对照组给予孕三烯酮治疗,观察组在对照组的基础上联合米非司酮治疗。治疗后,观察和比较两组的临床疗效,治疗前后血清VEGF、MMP-9、sICAM-1水平及临床症状、体征的变化。结果:治疗后,观察组总有效率显著高于对照组(P<0.05),两组患者血清VEGF、MMP-9、sICAM-1水平均较治疗前显著减低(P<0.05),且观察组血清VEGF、MMP-9、sICAM-1水平均明显低于对照组(P<0.05);两组患者治疗后痛经、非经期下腹痛、性交痛、子宫直肠窝结节粘连、子宫直肠窝触痛以及子宫活动受限的发生率均较治疗前显著降低,且观察组以上症状体征的发生率明显低于对照组(P<0.05)。结论:采用孕三烯酮联合米非司酮治疗子宫内膜异位症可有效提高其临床疗效,且安全性较高,可能与其显著降低患者血清VEGF、sICAM-1、MMP-9水平有关。 |
英文摘要: |
ABSTRACT Objective: To investigate the clinical efficacy of trienone combined with mifepristone in the Treatment of Endometriosis and its effects on the serum Levels of vascular endothelial growth factor(VEGF), matrix metalloprotein-9(MMP-9), soluble intercellular adhesion molecule-1(sICAM-1). Methods: 96 cases of patients with endometriosis treated from June 2017 to October 2018 in our hospital were selected and divided into the observation group and the control group according to different treatment. The control group was treated with trienone, while the observation group was treated with ultrasound guided the injection without water ethanol unite mifepristone for 6 months. Then the clinical effect, changes of serum VEGF, MMP-9, sICAM-1 levels and clinical symptoms and signs before and after treatment were observed and compared between two groups. Results: After treatment, the total effective rate of observation group was higher than that of the control group (P<0.05), the serumVEGF, MMP-9, sICAM-1 levels in both groups after the treatment were lower than those before treatment(P < 0.05), whih were higher in the observation group than those of the control group(P<0.05). The Clinical symptoms of Observation group were better than those of the control group(P<0.05). Conclusion: Trienone combination with mifepristone can achieve ideal curative effect in the treatment of endometriosis with high safety, it may be related to the decrease of VEGF, sICAM -1, MMP-9 levels. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|